A Clinical Study to Assess the Effect of a Dietary Supplement on Menstrual Cycle Symptoms

NCT07267728 | Completed

• 1 other identifier: 20736
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-group, virtual clinical trial evaluating the effects of a daily dietary supplement (DITTO Cycle Supplement) on menstrual cycle symptoms across three menstrual cycles. The study investigates changes in symptom severity and quality of life through validated questionnaires including the Menstrual Symptoms Questionnaire (MSQ).

Conditions

Premenstrual Syndrome; Menstrual Pain

Keywords

Bloating; Mood Disorders

Outcome Measures

Primary Outcomes (1)

• Change in Menstrual Symptoms Questionnaire (MSQ) Scores

  Change from baseline in menstrual symptom severity as measured by the Menstrual Symptoms Questionnaire (MSQ), including cramps, bloating, fatigue, mood swings, breast tenderness, headaches, anxiety, irritability, and difficulty concentrating.

  Baseline, End of Cycle 1(28 days), End of Cycle 2(28 days), End of Cycle 3 (28 days)

Secondary Outcomes (1)

• Change in Menstrual-Related Quality of Life

  Baseline, End of Cycle 1(28 days), End of Cycle 2(28 days), End of Cycle 3 (28 days)

Study Arms (1)

DITTO Cycle Supplement

EXPERIMENTAL

Participants will take two capsules of the DITTO Cycle Supplement once daily, starting two days after menstrual bleeding ends, for the duration of three menstrual cycles.

Dietary Supplement: DITTO Cycle Supplement

Interventions

DITTO Cycle Supplement DIETARY_SUPPLEMENT

The capsules should be taken in the morning with the first meal and a glass of water.

DITTO Cycle Supplement

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Female-at-birth
• Aged 18-45
• In the last three menstrual cycles, has experienced three or more of the following symptoms associated with their menstrual cycle: Menstrual cramps, Bloating, Breast tenderness, Headaches, Fatigue, Muscle aches and/or joint pain, Cravings, Mood swings, Low mood, Feelings of anxiety, Irritability, Difficulty concentrating
• Generally healthy - does not live with any uncontrolled chronic disease
• Has a regular menstrual cycle length, between 23 and 35 days
• Tracks their menstrual cycle and can predict their period dates
• Anyone willing to comply with study requirements
• Anyone with no known allergies to the ingredients listed in the product

You may not qualify if:

• Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders
• Women who are pregnant, breastfeeding, or trying to conceive
• Anyone unwilling to follow the study protocol
• Anyone in perimenopause, menopause, or experiencing menopausal-type symptoms
• Anyone with planned surgery during the study period
• Anyone with a history of substance abuse
• Anyone diagnosed with high blood pressure, high cholesterol, heart disease, heart attack, stroke, irregular heartbeat (AFib), clogged arteries, poor circulation, heart failure, or other heart conditions
• Anyone diagnosed with a hormone or reproductive health-related cancer or benign condition
• Anyone diagnosed with a menstrual health condition such as endometriosis, PCOS, or adenomyosis
• Anyone diagnosed with diabetes or other endocrine-related condition
• Anyone currently participating or planning to participate in a research study
• Anyone who has started, changed, or stopped taking hormonal birth control in the last three months
• Has a planned insertion or replacement of an IUD in the next 12 weeks

Sponsors & Collaborators

• Muse Nutrition Ltd: lead
• Citruslabs: collaborator

Study Sites (1)

Citruslabs

Las Vegas, Nevada, 89118, United States

Location

MeSH Terms

Conditions

Premenstrual Syndrome; Dysmenorrhea; Mood Disorders

Condition Hierarchy (Ancestors)

Menstruation Disturbances; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Pelvic Pain; Pain; Neurologic Manifestations; Signs and Symptoms; Mental Disorders

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 19, 2025
• First Posted: December 5, 2025
• Study Start: February 1, 2025
• Primary Completion: July 1, 2025
• Study Completion: July 1, 2025
• Last Updated: December 5, 2025

Record last verified: 2025-11

Locations

US (1)